Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects [Phase 1]

View source ↗

Summary

This Phase 1 trial of BAR 502 in healthy subjects intended for non-alcoholic fatty liver disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• BAR 502

Snippet

Sponsor: BAR Pharmaceuticals s.r.l. | Conditions: Non-Alcoholic Fatty Liver Disease | Phase 1 | Status: WITHDRAWN